Logo image of TYME

TYME TECHNOLOGIES INC (TYME) Stock Fundamental Analysis

NASDAQ:TYME - Nasdaq - US90238J1034 - Common Stock - Currency: USD

0.3107  +0.02 (+8.07%)

After market: 0.2852 -0.03 (-8.21%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to TYME. TYME was compared to 549 industry peers in the Biotechnology industry. The financial health of TYME is average, but there are quite some concerns on its profitability. TYME has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year TYME has reported negative net income.
TYME had negative earnings in each of the past 5 years.
In the past 5 years TYME always reported negative operating cash flow.
TYME Yearly Net Income VS EBIT VS OCF VS FCFTYME Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 -10M -20M -30M

1.2 Ratios

Industry RankSector Rank
ROA -30.18%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TYME Yearly ROA, ROE, ROICTYME Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 0 -100 -200 -300

1.3 Margins

TYME does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TYME Yearly Profit, Operating, Gross MarginsTYME Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022

More info and screens

6

2. Health

2.1 Basic Checks

TYME has about the same amout of shares outstanding than it did 1 year ago.
There is no outstanding debt for TYME. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
TYME Yearly Shares OutstandingTYME Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M
TYME Yearly Total Debt VS Total AssetsTYME Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M

2.2 Solvency

An Altman-Z score of 2.47 indicates that TYME is not a great score, but indicates only limited risk for bankruptcy at the moment.
TYME has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2.47
ROIC/WACCN/A
WACCN/A
TYME Yearly LT Debt VS Equity VS FCFTYME Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 20M -20M 40M 60M 80M 100M

2.3 Liquidity

A Current Ratio of 14.06 indicates that TYME has no problem at all paying its short term obligations.
A Quick Ratio of 14.06 indicates that TYME has no problem at all paying its short term obligations.
Industry RankSector Rank
Current Ratio 14.06
Quick Ratio 14.06
TYME Yearly Current Assets VS Current LiabilitesTYME Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M

More info and screens

0

3. Growth

3.1 Past

TYME shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 22.61%, which is quite impressive.
EPS 1Y (TTM)22.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-9.54%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

TYME is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -7.64% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-88.44%
EPS Next 2Y-11.67%
EPS Next 3Y-7.64%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
TYME Yearly Revenue VS EstimatesTYME Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 200K 400K 600K 800K 1M
TYME Yearly EPS VS EstimatesTYME Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 -0.1 -0.2 -0.3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TYME. In the last year negative earnings were reported.
Also next year TYME is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TYME Price Earnings VS Forward Price EarningsTYME Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA 1.02
TYME Per share dataTYME EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4

4.3 Compensation for Growth

A cheap valuation may be justified as TYME's earnings are expected to decrease with -7.64% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-11.67%
EPS Next 3Y-7.64%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TYME!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TYME TECHNOLOGIES INC

NASDAQ:TYME (9/16/2022, 8:00:02 PM)

After market: 0.2852 -0.03 (-8.21%)

0.3107

+0.02 (+8.07%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-30 2022-08-30/bmo
Earnings (Next)11-07 2022-11-07
Inst Owners0%
Inst Owner Change0%
Ins Owners16.62%
Ins Owner Change0%
Market Cap53.50M
Analysts82.86
Price Target9.69 (3018.76%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.72
P/tB N/A
EV/EBITDA 1.02
EPS(TTM)-0.14
EYN/A
EPS(NY)-0.25
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS0.43
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -30.18%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 14.06
Quick Ratio 14.06
Altman-Z 2.47
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)22.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-9.54%
EPS Next Y-88.44%
EPS Next 2Y-11.67%
EPS Next 3Y-7.64%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A